Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Cynomolgus IgG1 (AM122)

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Cynomolgus IgG1 (AM122) (SPD-M201) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with Cynomolgus IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 Protein.

Product Specifications

Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

CAS Number

9007-83-4

Host

HEK293

Origin Species

Cynomolgus

Target

Spike RBD

Conjugation

Unconjugated

Tag

Cynomolgus IgG1 | Cynomolgus Kappa

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.

Purity

0.95

Bioactivity

Immobilized SARS-CoV-2 Spike RBD, His Tag (Cat. No. SPD-C52H1) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Cynomolgus IgG1 (AM122) (Cat. No. SPD-M201) with a linear range of 0.4-25 ng/mL (QC tested).